Content Status

Type

Linked Node

H5Content
Content

The anti-TB drugs recommended for the treatment of Multi-drug Resistant (MDR)/ Rifampicin-resistant Tuberculosis (RR-TB) patients are grouped based on their efficacy, safety, experience of use of the drug and drug class.

Table: Grouping of DR-TB drugs as per the revised classification from World Health Organization (WHO); Source: Consolidated Guidelines for TB; Module 4: Treatment of Drug-resistant TB (2020), p27.
DRUG GROUP REASONS FOR INCLUSION IN THE CLASSIFICATION OF ANTI-TB DRUGS
Group A: Fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline and linezolid Considered highly effective and strongly recommended for inclusion in all regimens unless contraindicated
Group B: Clofazimine and cycloserine or terizidone Conditionally recommended as agents of the second choice based on their efficacy and safety
Group C: This includes all other medicines that can be used when a regimen cannot be composed with Group A and B agents Ranked and included by the relative balance of benefit to harm usually expected of each

 

Resources

 

 

Kindly provide your valuable feedback on the page to the link provided HERE

Content Creator

Reviewer